|TVM Capital China Limited||Managing Partner and CEO||China|
Seed funds crossing borders: How far and how fast is the early-stage investment market in biotech globalising?
Dr. Scherer serves as CEO for TVM China (based in Hong Kong). TVM China is supporting Western life science firms that want to access the fast growing Chinese market as well as Chinese life science investors and pharma companies interested in accessing Western innovation for the Chinese market.
Previously he consulted for MPM Capital focusing on deal sourcing for MPM in Europe. Mirko was also a co-founder and partner at KI Kapital which specialized in consulting in the life science industries.
Prior to working in the venture capital industry, Mirko co-founded GPC Biotech (Munich and Princeton, NJ) and served as its Chief Financial Officer for a decade. GPC Biotech engaged in numerous pharmaceutical alliances with companies such as Sanofi Aventis, Boehringer Ingelheim, Altana (now part of Takeda), Yakult and Pharmion (now part of Celgene). At GPC, Mirko was responsible for all financial, legal, corporate communication and governance topics. He was instrumental in numerous capital raisings (venture capital stage, IPO and follow on offerings in Germany as well as on NASDAQ), licensing transactions, mergers & acquisitions and other strategic transactions. Over the last 20 years Mirko has established an extensive network in the European, US and Chinese biotechnology and venture capital industry. Prior to his time at GPC Biotech Mirko worked as a consultant at the Boston Consulting Group. He has served on the Board of the Frankfurt Stock Exchange and is currently a board member of the Stichting Preferente Aandelen QIAGEN, and Aptorum Inc..
Mirko holds an MBA from Harvard Business School, Boston. He also earned a Doctorate in Finance from the European Business School in Oestrich-Winkel/Germany and a degree in business administration from the University of Mannheim/Germany.